Volume 25, Number 10—October 2019
Research
Economic Burden of West Nile Virus Disease, Quebec, Canada, 2012–2013
Table 3
Characteristic | WNF, n = 24 | WNM, n = 18 | WNE, n = 48† |
---|---|---|---|
Age group, y | |||
<50 | 7 (29) | 7 (39) | 6 (12) |
50–59 | 10 (42) | 7 (39) | 8 (17) |
≥60 |
7 (29) |
4 (22) |
34 (71) |
Sex | |||
M | 7 (29) | 8 (44) | 24 (50) |
F |
17 (71) |
10 (56)) |
24 (50) |
Hospitalization | 5 (21) | 17 (94) | 47 (98) |
Days hospitalized, median (range) | 4 (2–12) | 4 (1–36) | 12 (3–663) |
Intensive care | 0 | 0 | 22/47 (47) |
Complications | 0 | 3/17(18) | 21/47 (45) |
Death in hospital | 0 | 1/17 (6) | 10/47 (21) |
*Values are no. (%) or no. occurrences/no. hospitalized (%) unless otherwise indicated. WNE, West Nile encephalitis; WNF, West Nile fever; WNM, West Nile meningitis; WNV, West Nile virus.
†Includes WNE (n = 28), meningoencephalitis (n = 18), and acute flaccid paralysis (n = 2).
1Deceased.
Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.